HER2, a HER2-targeted immunotherapy, with plans for FDA submission following promising Phase 2b data in osteosarcoma.

OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has entered into ...

Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with ...

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

The FDA made strides in R/R T-cell lymphoma and breast cancer. An AI tool aids pathologists and other positive updates in gastric cancer and NSCLC.

OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today provided a corporate update to the ...

Three new cancer treatments are to be made available on the NHS in Scotland, as six drugs are given the green light for use.

Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines mark a significant milestone in breast cancer treatment, seamlessly integrating cutting-edge international research with Chinese ...

The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult pat ...